Humacyte, Inc. (HUMA) closed the most recent trading day at $0.56, moving -2% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.51% for the day. Meanwhile, the Dow experienced a rise of 0.93%, and the technology-dominated Nasdaq saw an increase of 0.48%.
Shares of the company have depreciated by 17.9% over the course of the past month, underperforming the Medical sector's loss of 3.38%, and the S&P 500's gain of 0.74%.
Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. On that day, Humacyte, Inc. is projected to report earnings of -$0.09 per share, which would represent year-over-year growth of 35.71%. Alongside, our most recent consensus estimate is anticipating revenue of $0.86 million, indicating a 14.67% upward movement from the same quarter last year.
HUMA's full-year Zacks Consensus Estimates are calling for earnings of -$0.4 per share and revenue of $4.05 million. These results would represent year-over-year changes of -53.85% and +98.48%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Right now, Humacyte, Inc. possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 172, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Humacyte, Inc. (HUMA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).